- Home
- CRTO vs MYGN Comparison
CRTO vs MYGN Comparison
Compare CRTO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- MYGN
- Stock Information
- Founded
- CRTO 2005
- MYGN 1991
- Country
- CRTO France
- MYGN United States
- Employees
- CRTO N/A
- MYGN N/A
- Industry
- CRTO Advertising
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CRTO Consumer Discretionary
- MYGN Health Care
- Exchange
- CRTO Nasdaq
- MYGN Nasdaq
- Market Cap
- CRTO 2.4B
- MYGN 2.0B
- IPO Year
- CRTO 2013
- MYGN 1995
- Fundamental
- Price
- CRTO $39.33
- MYGN $13.50
- Analyst Decision
- CRTO Buy
- MYGN Hold
- Analyst Count
- CRTO 10
- MYGN 11
- Target Price
- CRTO $51.11
- MYGN $24.27
- AVG Volume (30 Days)
- CRTO 297.1K
- MYGN 1.1M
- Earning Date
- CRTO 02-05-2025
- MYGN 02-25-2025
- Dividend Yield
- CRTO N/A
- MYGN N/A
- EPS Growth
- CRTO 1182.57
- MYGN N/A
- EPS
- CRTO 1.63
- MYGN N/A
- Revenue
- CRTO $1,946,556,000.00
- MYGN $823,600,000.00
- Revenue This Year
- CRTO N/A
- MYGN $13.82
- Revenue Next Year
- CRTO $6.05
- MYGN $4.59
- P/E Ratio
- CRTO $24.27
- MYGN N/A
- Revenue Growth
- CRTO N/A
- MYGN 12.15
- 52 Week Low
- CRTO $23.87
- MYGN $12.87
- 52 Week High
- CRTO $49.93
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CRTO 39.15
- MYGN 32.61
- Support Level
- CRTO $41.29
- MYGN $13.04
- Resistance Level
- CRTO $43.89
- MYGN $13.77
- Average True Range (ATR)
- CRTO 1.28
- MYGN 0.60
- MACD
- CRTO -0.50
- MYGN 0.14
- Stochastic Oscillator
- CRTO 4.80
- MYGN 24.51
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.